Drug Database
Back to search

Belgium· BE-AMP-SAM096887-00

Ludiomil 25 mg

A maprotiline product containing maprotiline hydrochloride, registered in Belgium by Amdipharm. The same ATC class is registered in 8 of our 19 countries.

ATC N06AA21

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedLudiomil 25 mgATCN06AA21REGISTER NO.BE-AMP-SAM096887-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about maprotiline hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Maprotiline is registered in 8 of 19 countries.

Countries holding a registration under ATC N06AA21 (maprotiline), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 4 of them publish a price we can compare per daily dose
Search maprotiline products by name

Maprotiline · ATC N06AA21

8 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of maprotiline costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Maprotiline · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • FR France$0.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Maprotiline Hydrochloride
Manufacturer
Amdipharm
Country
Belgium (BE)
ATC code
N06AA21
ATC class
Maprotiline
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0055202
  • be_apb
    0711077

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

335 interactions on record for maprotiline.

Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check maprotiline against other medicinesHow interaction checks work

Maprotiline · interactions on record

335 records

  • 55 severe
  • 204 moderate
  • 8 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe

68 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Maprotiline in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All maprotiline products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Austria · Ludiomil
  • Cyprus · Epalon
  • Germany · Maprotilin Neuraxpharm
  • Denmark · Ludiomil
  • Spain · Ludiomil
  • France · Ludiomil
  • Greece · Ludiomil
  • Italy · Ludiomil
  • Poland · Ludiomil
  • Portugal · Ludiomil
  • Slovakia · Ludiomil 25

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bd564b1b-8b12-47d4-8060-c7dce8596a13
GET /v1/drugs/bd564b1b-8b12-47d4-8060-c7dce8596a13?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Ludiomil 25 mg",
  "name_fr": "Ludiomil 25 mg",
  "name_nl": "Ludiomil 25 mg",
  "amp_code": "SAM096887-00",
  "strengths": [
    "25.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Maprotiline Hydrochloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Maprotiline",
  "authorisation_numbers": [
    "BE096887"
  ]
}
API referenceMCP serverPlans

See everything about maprotiline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console